FDA's deputy commissioner tells DIA attendees the Trump administration will keep pursuing Makary's user fee priorities as Congress weighs bipartisan riders on clinical trials, China competition and rare diseases.
PHILADELPHIA – Following the recent departures of FDA Commissioner Marty Makary and both of his center directors for drugs and biologics, the Trump administration will …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas. In the meeting,…
Pharma and rare disease advocates press FDA at public hearing on Makary's National Priority Voucher pilot, urging formal…
Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug…
With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across…
The White House is reviewing a new FDA-biopharma user fee deal that includes
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping…
